文献速递免疫规划传染病防控与疫情报告

prematurely terminated phase 2 randomised trial: single vs two-dose BNT162b2 in previously SARS-CoV-2 infected children 5-11 years old

A prematurely terminated phase 2, randomised trial to evaluate immunogenicity and reactogenicity of a single versus two-dose primary vaccination regimen of the mRNA vaccine BNT162b2 in previously SARS-CoV-2 infected children 5-11 years old (CoVacc trial).
PubMed 文献 · Vaccine · 2026-06-27

这项开放标签随机2期研究在5-11岁既往SARS-CoV-2感染儿童中比较单剂与两剂BNT162b2初免的免疫原性和反应原性,因接种意愿下降提前终止,仅纳入31人。第28天两剂组与单剂组中和抗体GMT分别为1801.1 IU/mL和1715.5 IU/mL,单剂非劣效性未能证明(GMR 0.9,95%CI 0.5-1.6)。两组免疫应答持久且耐受良好。

要点

  • 既往感染儿童单剂BNT162b2免疫原性非劣效于两剂未能证明。
  • 第28天两组中和抗体GMT均较高,6和12个月仍>100 IU/mL。
  • 两组全身不良事件≥2级比例无统计学差异。

核心结论

  • 两种方案均诱导稳健持久免疫应答,单剂在既往感染儿童中可能起加强体液免疫作用。
  • 因提前终止,主要非劣效比较统计效能不足。
  • 疫苗在两组中耐受良好。

研究设计与样本

  • 开放标签随机2期研究,5-11岁既往SARS-CoV-2感染儿童1:1随机接受1剂或2剂BNT162b2,间隔3-12周。
  • 共纳入31名来自3个欧洲国家的参与者,中位年龄9岁(IQR 7-10),2022年5月至2024年1月入组。
  • 两剂组15人,单剂组16人;试验因年龄合格儿童COVID-19疫苗接种兴趣下降提前终止。

主要发现

  • 第28天野生型SARS-CoV-2中和抗体GMT两剂组1801.1 IU/mL(95%CI 1357.9-2388.9),单剂组1715.5 IU/mL(95%CI 1064.2-2765.4)。
  • 单剂对两剂的GMR为0.9(95%CI 0.5-1.6),非劣效性界值为GMT 1.5倍变化,未能证明非劣效。
  • 两组6和12个月中和抗体滴度均保持>100 IU/mL。
  • 第28天两剂组8人(53%)、单剂组5人(31%)报告接种后7天内≥2级全身不良事件(P=0.18)。

临床怎么用

  • 对于既往SARS-CoV-2感染的5-11岁儿童,单剂BNT162b2可诱导与两剂相当的持久中和抗体应答。
  • 单剂方案可能降低全身不良反应发生比例,但差异未达统计学显著。
  • 临床决策需考虑研究因样本量小和提前终止导致的统计效能不足。

局限性

  • 试验提前终止,主要非劣效比较统计效能不足。
  • 样本量小(共31人),来自3个欧洲国家。
  • 开放标签设计可能影响安全性报告。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: This open-label randomised phase 2 study aimed to determine whether a single versus two-dose BNT162b2 primary vaccination regimen in children 5 to 11 years old with prior SARS-CoV-2 infection was non-inferior in terms of immunogenicity and superior in terms of safety and reactogenicity. METHODS: Participants were randomly assigned (1:1) to receive either one or two doses, spaced 3 to 12-weeks. The primary endpoint was geometric mean ratio (GMR) of neutralizing antibodies against wild-type SARS-CoV-2 at 28 days post-vaccination with non-inferiority margin defined as a 1.5-fold change in geometric mean titers (GMT). Secondary endpoints included safety and reactogenicity profile and immunogenicity up to 12 months against wild-type and Variants of Concern (VOCs). RESULTS: In total 31 participants from 3 European countries (median age 9, IQR7-10) were enrolled from May 2022 to January 2024, when the trial was prematurely terminated due to declining interest in COVID-19 vaccination among age-eligible children. Of these, 15 received two doses, and 16 received one. At day 28, GMT of neutralizing antibodies against wild-type SARS-CoV-2 was 1801.1 IU/mL(95%CI:1357.9-2388.9) in the two-dose arm and 1715.5 IU/mL(95%CI:1064.2-2765.4) in the single-dose arm. However, the non-inferiority of the single-dose could not be demonstrated (GMR:0.9; 95%CI:0.5-1.6). Titers remained above 100 IU/mL in both groups at 6 and 12 months. Both schedules elicited high anti-RBD IgG titers against wild-type and neutralizing titers against BA.5 variant at day 28. Eight participants (53%) in the two-dose arm and five (31%) in the single-dose reported a systemic adverse event grade ≥ 2 (P = 0.18) within 7 days of vaccination. CONCLUSIONS: Both regimens induced robust and sustained immune responses consistent with the possibility that, in children with prior infection, a single dose functions immunologically as a booster of the humoral response. However, the premature termination renders the primary non-inferiority comparison statistically underpowered. The vaccine was well tolerated in both groups. EudraCT registration: 2021-005043-71.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Prat-Aymerich C, Yeghiazaryan L, Pathirana RD, et al. A prematurely terminated phase 2, randomised trial to evaluate immunogenicity and reactogenicity of a single versus two-dose primary vaccination regimen of the mRNA vaccine BNT162b2 in previously SARS-CoV-2 infected children 5-11 years old (CoVacc trial). Vaccine. 2026. PMID: 42364277. doi:10.1016/j.vaccine.2026.128769

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。